PROTOCOL NRG-HN003 - Temporarily Closed to Accrual

NRG-HN003, “A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC),” is temporarily closed to accrual effective immediately because the expansion cohort has enrolled 20 potentially evaluable patients.

The trial will be closed for at least 11 weeks until all patients complete the DLT evaluation period.  If all patients remain evaluable, a broadcast will be sent announcing final closure. Otherwise, the study will reopen for additional enrollment.

Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
Twitter
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse